TLR agonist at antigen release, addressing threshold drift
TLR agonist (tlr pathway agonism) acts at the antigen release step of the cancer-immunity cycle. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the antigen release step of the cancer-immunity cycle (capacitor regime, position P1), TLR agonist acts via tlr pathway agonism. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation. The intervention's regime-type class lines up with the position's regime, and failure_threshold_drift belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p1
- Failure modes
- failure_threshold_drift
Evidence at generation
"tlr agonist" AND "cancer immunotherapy"
- PMID 37802276
A multi-functional drug delivery nanosystem release of TLR-7 immunostimulant and OKT3 induced efficient cancer immunotherapy.
- PMID 29702142
Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
- PMID 39937883
Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade.
- PMID 32966047
Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
- PMID 39606250
Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy.
Targets: —
Not found in ChEMBL: TLR agonist
tlr agonist cancer immunotherapy
- NCT00453050
Melanoma (Skin)
Primary: Toxicity and tolerability by CTCAE version 3.0
- NCT04278144
HER2-positive Solid Tumors
Primary: Incidence of adverse events (AEs) and serious adverse events (SAEs)
- NCT04883645
Oral Squamous Cell Carcinoma
Primary: Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response
- NCT01421017
Breast Cancer
Primary: Systemic Tumor Response Rates (Complete Response+Partial Response)
- NCT04840394
Tumor, Solid
Primary: Safety and Tolerability: incidence of adverse events and any dose limiting toxicity
Status timeline
- Draft2026-05-28T23:27:38Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system
- Published2026-05-29T06:35:42Z
Published as part of the first 5-hypothesis daily batch. Engine v0.1.1: verb_target-aware combinatorial walker, sub-regime failure pool, lowercase evidence queries. Operator review pass: kept as-is.
by raimo